SUTRO BIOPHARMA, INC.
No enriched coverage for $STRO in the last 7 days.
No SEC Form 4 filings for $STRO in the last 30 days.
See all $STRO insider activity →Wedbush reiterated an Outperform rating and $60 price target for Sutro Biopharma, implying 470.3% upside from the Oct 14 close. The firm cited strong clinical data for lead candidates, including a 62% ORR for STRO-004, and a robust pipeline.
Sutro Biopharma (NASDAQ:STRO) reported quarterly revenue of $9.8m, 11% below analyst expectations, and a statutory loss per share of $2.33, 6.2% worse than forecast. For 2026, 12 analysts project revenue of $44.4m and losses of $8.73 per share. The average price target fell 5.4% to $50.33, with targets ranging $34 to $61.
SUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study – Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK
Recent STRO coverage spans financial news, earnings and corporate actions.
Wedbush reiterated an Outperform rating and $60 price target for Sutro Biopharma, implying 470.3% upside from the Oct 14 close. The firm cited strong clinical data for lead candidates, including a 62% ORR for STRO-004, and a robust pipeline.
Analyst target cut despite unchanged revenue and loss forecasts suggests valuation pressure from weaker-than-expected latest quarter.
STRO-004 early clinical signals and cash runway guidance are the core near-term drivers for STRO sentiment and risk appetite.
Buy initiation can attract attention in biotech, potentially supporting speculative flows.
Buy initiation can be a positive catalyst for STRO sentiment, especially for biotech traders.
AlphAI scores every news story that mentions STRO with an AI model for sentiment and relevance, and aggregates insider trades from SUTRO BIOPHARMA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wedbush reiterated an Outperform rating and $60 price target for Sutro Biopharma, implying 470.3% upside from the Oct 14 close. The firm cited strong clinical data for lead candidates, including a 62% ORR for STRO-004, and a robust pipeline.
1 min readSutro Biopharma (NASDAQ:STRO) reported quarterly revenue of $9.8m, 11% below analyst expectations, and a statutory loss per share of $2.33, 6.2% worse than forecast. For 2026, 12 analysts project revenue of $44.4m and losses of $8.73 per share. The average price target fell 5.4% to $50.33, with targets ranging $34 to $61.
3 min readSUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study – Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK
6 min readA Wall Street analyst roundup cites multiple rating changes ahead of next week’s CPI and PPI. Baird cut Trade Desk (TTD) to Neutral, target $9 from $27. Citigroup downgraded JetBlue (JBLU) to Sell, target $5.30. Morgan Stanley started Baker Hughes (BKR) at Overweight, $70. Other calls include Etsy (ETSY) upgrade to $100 and Tower Semiconductor (TSEM) Buy at $367.
7 min read24/7 Wall St. lists Friday analyst research calls. JPMorgan upgraded Etsy to Overweight, target $100 (from $85). BNP Paribas upgraded Instacart to Neutral, $56. BMO cut HubSpot to Market Perform, $215. Citigroup downgraded JetBlue to Sell, $5.30. Several other upgrades, downgrades, and initiations include Baker Hughes (BKR) Overweight, $70 and Trade Desk (TTD) downgraded to Neutral, $9.
6 min readStrongPoint, a Norway-based grocery retail tech company, said Q2 revenue fell 2% year over year to NOK 342 million after the exit of a former Electronic Shelf Label (ESL) partner. EBITDA was NOK 5 million, including NOK 4 million in one-time costs. Operating and net income were negative. The company cited Nordic revenue down 22% and expects U.S. profitable growth.
4 min readSUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001382101 0001382101 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2
2 min readSutro Biopharma (NASDAQ:STRO) has reported a strong financial position for full-year 2025, with $141.4 million in cash and marketable securities and an extended financial runway into Q2 2028. The company is advancing its ADC pipeline, including progressing STRO-004 through Phase 1 trials, accelerating STRO-227 towards an IND submission, and entering STRO-006 into clinical development. Strategic partnerships, such as with Astellas Pharma, further validate Sutro's proprietary cell-free platform for developing next-generation cancer treatments.
4 min readWells Fargo analyst Eva Fortea Verdejo has upgraded Sutro Biopharma (STRO) from Equal-Weight to Overweight, significantly increasing the price target from $8.00 to $27.00. This upgrade, reflecting a 237.50% change, signals a more optimistic outlook for the company's future performance in the biotech sector. Sutro Biopharma is a clinical-stage company developing biopharmaceutical products for cancer and autoimmune disorders using its proprietary XpressCF platform.
2 min readSutro Biopharma's Chief Administrative Officer and General Counsel, David Pauling, reported several equity transactions including receiving new awards of 4,200 Restricted Stock Units (RSUs) and stock options for 33,600 shares. The report also detailed the vesting and settlement of previously awarded RSUs. Additionally, some common shares were withheld to cover tax obligations related to RSU settlements, which the company clarified do not represent market sales by Pauling.
2 min read
